Suppr超能文献

益生菌:最新进展

Probiotics: an update.

作者信息

Vandenplas Yvan, Huys Geert, Daube Georges

机构信息

UZ Brussel, Department of Pediatrics, Vrije Universiteit Brussel, Brussels, Belgium.

Laboratory of Microbiology & BCCM/LMG Bacteria Collection, Faculty of Sciences, Ghent University, Ghent, Belgium.

出版信息

J Pediatr (Rio J). 2015 Jan-Feb;91(1):6-21. doi: 10.1016/j.jped.2014.08.005. Epub 2014 Oct 23.

Abstract

OBJECTIVE

Triggered by the growing knowledge on the link between the intestinal microbiome and human health, the interest in probiotics is ever increasing. The authors aimed to review the recent literature on probiotics, from definitions to clinical benefits, with emphasis on children.

SOURCES

Relevant literature from searches of PubMed, CINAHL, and recent consensus statements were reviewed.

SUMMARY OF THE FINDINGS

While a balanced microbiome is related to health, an imbalanced microbiome or dysbiosis is related to many health problems both within the gastro-intestinal tract, such as diarrhea and inflammatory bowel disease, and outside the gastro-intestinal tract such as obesity and allergy. In this context, a strict regulation of probiotics with health claims is urgent, because the vast majority of these products are commercialized as food (supplements), claiming health benefits that are often not substantiated with clinically relevant evidence. The major indications of probiotics are in the area of the prevention and treatment of gastro-intestinal related disorders, but more data has become available on extra-intestinal indications. At least two published randomized controlled trials with the commercialized probiotic product in the claimed indication are a minimal condition before a claim can be sustained. Today, Lactobacillus rhamnosus GG and Saccharomyces boulardii are the best-studied strains. Although adverse effects have sporadically been reported, these probiotics can be considered as safe.

CONCLUSIONS

Although regulation is improving, more stringent definitions are still required. Evidence of clinical benefit is accumulating, although still missing in many areas. Misuse and use of products that have not been validated constitute potential drawbacks.

摘要

目的

随着对肠道微生物群与人类健康之间联系的认识不断增加,人们对益生菌的兴趣日益浓厚。作者旨在综述关于益生菌的最新文献,内容涵盖从定义到临床益处,重点关注儿童。

资料来源

对PubMed、CINAHL检索出的相关文献以及近期的共识声明进行了综述。

研究结果总结

虽然平衡的微生物群与健康相关,但微生物群失衡或生态失调与许多健康问题有关,这些问题既包括胃肠道内的问题,如腹泻和炎症性肠病,也包括胃肠道外的问题,如肥胖和过敏。在这种情况下,迫切需要对具有健康声称的益生菌进行严格监管,因为这些产品绝大多数作为食品(补充剂)商业化销售,声称具有健康益处,但往往缺乏临床相关证据的支持。益生菌的主要适应证是预防和治疗胃肠道相关疾病,但关于肠道外适应证的可用数据越来越多。在一项声称的适应证中,至少有两项已发表的关于商业化益生菌产品的随机对照试验是维持该声称的最低条件。如今,鼠李糖乳杆菌GG和布拉酵母菌是研究最多的菌株。虽然偶尔有不良反应的报道,但这些益生菌可被视为安全的。

结论

虽然监管正在改善,但仍需要更严格的定义。临床益处的证据正在积累,尽管在许多领域仍然缺乏。滥用和使用未经验证的产品构成潜在弊端。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验